Literature DB >> 27365461

Whole exome sequencing in families at high risk for Hodgkin lymphoma: identification of a predisposing mutation in the KDR gene.

Melissa Rotunno1, Mary L McMaster1, Joseph Boland2, Sara Bass2, Xijun Zhang2, Laurie Burdett2, Belynda Hicks2, Sarangan Ravichandran3, Brian T Luke3, Meredith Yeager2, Laura Fontaine4, Paula L Hyland1, Alisa M Goldstein1, Stephen J Chanock5, Neil E Caporaso1, Margaret A Tucker6, Lynn R Goldin7.   

Abstract

Hodgkin lymphoma shows strong familial aggregation but no major susceptibility genes have been identified to date. The goal of this study was to identify high-penetrance variants using whole exome sequencing in 17 Hodgkin lymphoma prone families with three or more affected cases or obligate carriers (69 individuals), followed by targeted sequencing in an additional 48 smaller HL families (80 individuals). Alignment and variant calling were performed using standard methods. Dominantly segregating, rare, coding or potentially functional variants were further prioritized based on predicted deleteriousness, conservation, and potential importance in lymphoid malignancy pathways. We selected 23 genes for targeted sequencing. Only the p.A1065T variant in KDR (kinase insert domain receptor) also known as VEGFR2 (vascular endothelial growth factor receptor 2) was replicated in two independent Hodgkin lymphoma families. KDR is a type III receptor tyrosine kinase, the main mediator of vascular endothelial growth factor induced proliferation, survival, and migration. Its activity is associated with several diseases including lymphoma. Functional experiments have shown that p.A1065T, located in the activation loop, can promote constitutive autophosphorylation on tyrosine in the absence of vascular endothelial growth factor and that the kinase activity was abrogated after exposure to kinase inhibitors. A few other promising mutations were identified but appear to be "private". In conclusion, in the largest sequenced cohort of Hodgkin lymphoma families to date, we identified a causal mutation in the KDR gene. While independent validation is needed, this mutation may increase downstream tumor cell proliferation activity and might be a candidate for targeted therapy. Copyright© Ferrata Storti Foundation.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27365461      PMCID: PMC5004465          DOI: 10.3324/haematol.2015.135475

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  38 in total

1.  A genome screen of families at high risk for Hodgkin lymphoma: evidence for a susceptibility gene on chromosome 4.

Authors:  L R Goldin; M L McMaster; M Ter-Minassian; S Saddlemire; B Harmsen; G Lalonde; M A Tucker
Journal:  J Med Genet       Date:  2005-07       Impact factor: 6.318

2.  The familial risk of Hodgkin's lymphoma ranks among the highest in the Swedish Family-Cancer Database.

Authors:  A Altieri; K Hemminki
Journal:  Leukemia       Date:  2006-08-31       Impact factor: 11.528

3.  HLA-DR, HLA-DQ, and TAP genes in familial Hodgkin disease.

Authors:  Lea C Harty; Albert Y Lin; Alisa M Goldstein; Elaine S Jaffe; Mary Carrington; Margaret A Tucker; William S Modi
Journal:  Blood       Date:  2002-01-15       Impact factor: 22.113

4.  Association with HLA class I in Epstein-Barr-virus-positive and with HLA class III in Epstein-Barr-virus-negative Hodgkin's lymphoma.

Authors:  A Diepstra; M Niens; E Vellenga; G W van Imhoff; I M Nolte; M Schaapveld; G van der Steege; A van den Berg; R E Kibbelaar; G J te Meerman; S Poppema
Journal:  Lancet       Date:  2005 Jun 25-Jul 1       Impact factor: 79.321

5.  Phase II study of alisertib, a selective Aurora A kinase inhibitor, in relapsed and refractory aggressive B- and T-cell non-Hodgkin lymphomas.

Authors:  Jonathan W Friedberg; Daruka Mahadevan; Erin Cebula; Daniel Persky; Izidore Lossos; Amit B Agarwal; Jungah Jung; Richard Burack; Xiaofei Zhou; E Jane Leonard; Howard Fingert; Hadi Danaee; Steven H Bernstein
Journal:  J Clin Oncol       Date:  2013-09-16       Impact factor: 44.544

6.  Mutations in a gene encoding a midbody kelch protein in familial and sporadic classical Hodgkin lymphoma lead to binucleated cells.

Authors:  Stephen J Salipante; Matthew E Mealiffe; Jeremy Wechsler; Maxwell M Krem; Yajuan Liu; Shinae Namkoong; Govind Bhagat; Tomas Kirchhoff; Kenneth Offit; Henry Lynch; Peter H Wiernik; Mikhail Roshal; Mary Lou McMaster; Margaret Tucker; Jonathan R Fromm; Lynn R Goldin; Marshall S Horwitz
Journal:  Proc Natl Acad Sci U S A       Date:  2009-08-12       Impact factor: 11.205

7.  KDR activating mutations in human angiosarcomas are sensitive to specific kinase inhibitors.

Authors:  Cristina R Antonescu; Akihiko Yoshida; Tianhuo Guo; Ning-En Chang; Lei Zhang; Narasimhan P Agaram; Li-Xuan Qin; Murray F Brennan; Samuel Singer; Robert G Maki
Journal:  Cancer Res       Date:  2009-09-01       Impact factor: 12.701

8.  Patterns of somatic mutation in human cancer genomes.

Authors:  Christopher Greenman; Philip Stephens; Raffaella Smith; Gillian L Dalgliesh; Christopher Hunter; Graham Bignell; Helen Davies; Jon Teague; Adam Butler; Claire Stevens; Sarah Edkins; Sarah O'Meara; Imre Vastrik; Esther E Schmidt; Tim Avis; Syd Barthorpe; Gurpreet Bhamra; Gemma Buck; Bhudipa Choudhury; Jody Clements; Jennifer Cole; Ed Dicks; Simon Forbes; Kris Gray; Kelly Halliday; Rachel Harrison; Katy Hills; Jon Hinton; Andy Jenkinson; David Jones; Andy Menzies; Tatiana Mironenko; Janet Perry; Keiran Raine; Dave Richardson; Rebecca Shepherd; Alexandra Small; Calli Tofts; Jennifer Varian; Tony Webb; Sofie West; Sara Widaa; Andy Yates; Daniel P Cahill; David N Louis; Peter Goldstraw; Andrew G Nicholson; Francis Brasseur; Leendert Looijenga; Barbara L Weber; Yoke-Eng Chiew; Anna DeFazio; Mel F Greaves; Anthony R Green; Peter Campbell; Ewan Birney; Douglas F Easton; Georgia Chenevix-Trench; Min-Han Tan; Sok Kean Khoo; Bin Tean Teh; Siu Tsan Yuen; Suet Yi Leung; Richard Wooster; P Andrew Futreal; Michael R Stratton
Journal:  Nature       Date:  2007-03-08       Impact factor: 49.962

9.  Identification of homozygous deletion in ACAN and other candidate variants in familial classical Hodgkin lymphoma by exome sequencing.

Authors:  Heikki Ristolainen; Outi Kilpivaara; Peter Kamper; Minna Taskinen; Silva Saarinen; Sirpa Leppä; Francesco d'Amore; Lauri A Aaltonen
Journal:  Br J Haematol       Date:  2015-02-25       Impact factor: 6.998

10.  Guanine holes are prominent targets for mutation in cancer and inherited disease.

Authors:  Albino Bacolla; Nuri A Temiz; Ming Yi; Joseph Ivanic; Regina Z Cer; Duncan E Donohue; Edward V Ball; Uma S Mudunuri; Guliang Wang; Aklank Jain; Natalia Volfovsky; Brian T Luke; Robert M Stephens; David N Cooper; Jack R Collins; Karen M Vasquez
Journal:  PLoS Genet       Date:  2013-09-26       Impact factor: 5.917

View more
  12 in total

1.  Evaluating a CLL susceptibility variant in ITGB2 in families with multiple subtypes of hematological malignancies.

Authors:  Nicholas B Blackburn; James R Marthick; Annette Banks; Jac C Charlesworth; Katherine A Marsden; Ray M Lowenthal; John Blangero; Joanne L Dickinson
Journal:  Blood       Date:  2017-05-10       Impact factor: 22.113

Review 2.  Genomic approaches to accelerate cancer interception.

Authors:  Jennifer Beane; Joshua D Campbell; Julian Lel; Jessica Vick; Avrum Spira
Journal:  Lancet Oncol       Date:  2017-07-26       Impact factor: 41.316

3.  Whole exome sequencing in families with CLL detects a variant in Integrin β 2 associated with disease susceptibility.

Authors:  Lynn R Goldin; Mary L McMaster; Melissa Rotunno; Sarah E M Herman; Kristine Jones; Bin Zhu; Joseph Boland; Laurie Burdett; Belynda Hicks; Sarangan Ravichandran; Brian T Luke; Meredith Yeager; Laura Fontaine; Alisa M Goldstein; Stephen J Chanock; Margaret A Tucker; Adrian Wiestner; Gerald Marti; Neil E Caporaso
Journal:  Blood       Date:  2016-09-14       Impact factor: 22.113

4.  How I diagnose and manage individuals at risk for inherited myeloid malignancies.

Authors: 
Journal:  Blood       Date:  2016-07-28       Impact factor: 22.113

Review 5.  A Systematic Literature Review of Whole Exome and Genome Sequencing Population Studies of Genetic Susceptibility to Cancer.

Authors:  Alisa M Goldstein; Elizabeth M Gillanders; Melissa Rotunno; Rolando Barajas; Mindy Clyne; Elise Hoover; Naoko I Simonds; Tram Kim Lam; Leah E Mechanic
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2020-05-28       Impact factor: 4.254

6.  Germline mutations in Protection of Telomeres 1 in two families with Hodgkin lymphoma.

Authors:  Mary L McMaster; Chongkui Sun; Maria T Landi; Sharon A Savage; Melissa Rotunno; Xiaohong R Yang; Kristine Jones; Aurélie Vogt; Amy Hutchinson; Bin Zhu; Mingyi Wang; Belynda Hicks; Anand Thirunavukarason; Douglas R Stewart; Stella Koutros; Alisa M Goldstein; Stephen J Chanock; Neil E Caporaso; Margaret A Tucker; Lynn R Goldin; Yie Liu
Journal:  Br J Haematol       Date:  2018-05       Impact factor: 6.998

Review 7.  Nonclonal Chromosome Aberrations and Genome Chaos in Somatic and Germ Cells from Patients and Survivors of Hodgkin Lymphoma.

Authors:  Sara Frias; Sandra Ramos; Consuelo Salas; Bertha Molina; Silvia Sánchez; Roberto Rivera-Luna
Journal:  Genes (Basel)       Date:  2019-01-10       Impact factor: 4.096

8.  Combined linkage and association analysis of classical Hodgkin lymphoma.

Authors:  Alastair Lawrie; Shuo Han; Amit Sud; Fay Hosking; Timothee Cezard; David Turner; Caroline Clark; Graeme I Murray; Dominic J Culligan; Richard S Houlston; Mark A Vickers
Journal:  Oncotarget       Date:  2018-04-17

9.  Familial Cancer Variant Prioritization Pipeline version 2 (FCVPPv2) applied to a papillary thyroid cancer family.

Authors:  Abhishek Kumar; Obul Reddy Bandapalli; Nagarajan Paramasivam; Sara Giangiobbe; Chiara Diquigiovanni; Elena Bonora; Roland Eils; Matthias Schlesner; Kari Hemminki; Asta Försti
Journal:  Sci Rep       Date:  2018-08-02       Impact factor: 4.379

10.  Pedigree based DNA sequencing pipeline for germline genomes of cancer families.

Authors:  Asta Försti; Abhishek Kumar; Nagarajan Paramasivam; Matthias Schlesner; Calogerina Catalano; Dagmara Dymerska; Jan Lubinski; Roland Eils; Kari Hemminki
Journal:  Hered Cancer Clin Pract       Date:  2016-08-09       Impact factor: 2.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.